Panobinostat plus bortezomib and dexamethasone in relapsed/relapsed and refractory myeloma: outcomes by prior treatment
Richardson PG (1), Hungria VT (2), Yoon SS (3), Beksac M (4), Dimopoulos MA (5), Elghandour A (6), Jedrzejczak WW (7), Guenther A (8), Na Nakorn T (9), Siritanaratkul N (10), Schlossman RL (11), Hou J (12), Moreau P (13), Lonial S (14), Lee JH (15), Einsele H (16), Sopala M (17), Bengoudifa BR (17), Corrado C (17), Binlich F (18), San-Miguel JF (19). (1) Dana-Farber Cancer Institute, Boston, MA, United States; email@example.com.
(2) Irmandade da Santa Casa de Misericordia de Sao Paulo, Sao Paulo, Brazil;
(3) Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, Republic of;
(4) Ankara University School of Medicine, Ankara, Turkey;
(5) National and Kapodistrian University of Athens, Athens, Greece;
(6) Alexandria University, Alexandria, Egypt;
(7) Medical University of Warsaw, Warsaw, Poland;
(8) Division of Stem Cell Transplantation and Immunotherapy, 2nd Department of Medicine, University Hospital Schleswig-Holstein and University of Kiel, Kiel, Germany;
(9) King Chulalongkorn Memorial Hospital and Chulalongkorn University, Bangkok, Thailand;
(10) Siriraj Hospital, Bangkok, Thailand;
(11) Dana-Farber Cancer Institute, Boston, MA, United States;
(12) Chang Zheng Hospital, Shanghai, China;
(13) University Hospital of Nantes, Nantes, France;
(14) Winship Cancer Institute, Emory University, Atlanta, GA, United States;
(15) Department of Internal Medicine, Gachon University Gil Hospital, Incheon, Korea, Republic of;
(16) Medizinische Klinik und Poliklinik II, University of Wuerzburg, Wuerzburg, Germany;
(17) Novartis Pharma AG, Basel, Switzerland;
(18) Novartis Pharma SAS, Rueil-Malmaison, France;
(19) Clinica Universidad de Navarra, CIMA, IDISNA, Pamplona, Spain.
Date: Dec 2, 2015Haematology and Hameotherapy
Panobinostat is a potent pan-deacetylase inhibitor that affects the growth and survival of multiple myeloma (MM) cells through alteration of epigenetic mechanisms and protein metabolism. Panobinostat plus bortezomib and dexamethasone (PAN-BTZ-Dex) led to a significant increase in progression-free survival (PFS) vs placebo plus bortezomib and dexamethasone (Pbo-BTZ-Dex) in patients with relapsed or relapsed and refractory MM in the phase 3 PANORAMA 1 trial.
This subgroup analysis evaluated outcomes of patients in the PANORAMA 1 trial based on prior treatment: prior IMiD (n = 485); prior bortezomib plus IMiD (n = 193); and ≥ 2 prior regimens including bortezomib and an IMiD (n = 147). Median PFS for PAN-BTZ-Dex vs Pbo-BTZ-Dex across subgroups were as follows: prior IMiD (12.3 vs 7.4 months; hazard ratio [HR] 0.54; 95% CI, 0.43-0.68), prior bortezomib plus IMiD (10.6 vs 5.8 months; HR 0.52; 95% CI, 0.36-0.76), and ≥ 2 prior regimens including bortezomib and an IMiD (12.5 vs 4.7 months; HR 0.47; 95% CI, 0.31-0.72). Common grade 3/4 adverse events and laboratory abnormalities in patients who received PAN-BTZ-Dex across the prior treatment groups included thrombocytopenia, lymphopenia, neutropenia, diarrhea, and asthenia/fatigue.
Incidence of on-treatment deaths among patients who received prior bortezomib and IMiD (regardless of number of prior regimens) were similar between treatment arms.
This analysis demonstrated a clear PFS benefit of 7.8 months for PAN-BTZ-Dex among patients who received ≥ 2 prior regimens including bortezomib and an IMiD, a population with limited treatment options and poorer prognosis.
CITATION Blood. 2015 Dec 2. pii: blood-2015-09-665018.
you maybe interested
The Clínica is the greater private hospital with technological equipment of Spain, all in a single center.
The professionals of the Clínica perform continuous research and training, always to the benefit of the patient.
Learn why we are different from other healthcare centers. Quality, speed, comfort and results.